How to Localize Labels and Instructions for Overseas Registration of Implantable Medical Devices

Key Summary

For overseas registration of implantable medical devices, localization of labels and instructions for use must be treated as part of the registration strategy, not as a simple translation exercise. Companies should first determine whether the product falls within the target country's medical device regulatory scope, then confirm the registration pathway based on risk classification, assess whether existing NMPA, CE, FDA, or other documentation can be reused, and identify the local agent or authorized representative. Labeling and instructions for use require not only language localization but also compliance with local regulations, product standards, warning statements, symbols, units, UDI requirements, storage conditions, manufacturer and agent information, and more. The content must be consistent with the technical file, risk management report, and clinical evaluation conclusions; otherwise, deficiencies or disputes over clinical evaluation may arise. Common risks include direct machine translation, copying NMPA labels, omitting registration certificate numbers or agent addresses, ignoring terminology consistency in less common languages, failing to establish post-market change control, and version confusion in multi-country registration. Companies should prepare target language versions, translation accuracy declarations, symbol explanations, UDI plans, and version control procedures in advance, and agree with the local agent on responsibilities for changes and renewal. If labels and instructions are updated after market launch, companies must assess whether filing or registering a change with the regulatory authority is required to avoid compromising the validity of the certificate. For GHWP member states, core technical files can be reused, but labels and instructions must be localized country by country; a single version cannot be used universally.

Applicable Scenarios and Core Issues

Implantable medical devices include orthopedic implants, cardiovascular implants, neurostimulators, artificial joints, and similar products. When applying for registration with overseas market regulators, labels and instructions for use are often the most underestimated aspect. Many companies focus on product testing, clinical evaluation, and quality management systems, only to discover during submission or deficiency response that the labeling does not meet the target country's requirements.

Localization is not the same as translation. It requires converting the original country's labeling content into content that is recognized by the target country's regulator, while preserving the integrity and safety of technical information. Different countries have varying requirements for label text, language, font, symbols, units, warnings, single-use indications, UDI marks, and manufacturer and agent information.

Companies first need to determine whether the product is regulated as a medical device in the target country and its regulatory classification. For example, some low-risk products may be exempt from registration, but labeling must still meet general requirements; high-risk implantable products generally require registration and submission of labels and instructions as part of the registration dossier.

Registration Decision Logic

The first step is to determine whether the product falls within the target country's medical device regulatory scope. If it does, the risk class must be assigned—for example, under the EU MDR, classes range from I, IIa, IIb, to III, and similar classifications exist across Southeast Asian countries. The risk class determines the registration pathway, the depth of technical file review, and the review focus for labeling.

The second step is to assess reusability of existing documentation. If the company already has NMPA registration, CE certification, or FDA clearance, many technical documents can be reused, such as biocompatibility data, risk management reports, and preclinical testing. However, labels and instructions must be checked for target-language versions and local requirements. For instance, CE marking and FDA symbol systems cannot be directly transferred to GHWP member states.

The third step is to confirm who is responsible for localization. The company must designate the overseas registration applicant and contract a local agent or authorized representative. The local agent's name, address, and contact details on labels must be accurate, and the agent must assist with post-market surveillance and changes. Incorrect agent information can lead to rejection of the registration application.

The fourth step is to establish a localization template. Based on the target country's regulatory labeling guidelines, UDI rules, language requirements, and ISO 15223-1 symbol standards, create product label and instruction templates. For multi-country GHWP registrations, a unified core content can be maintained, with country-specific additions, but mixing versions across countries must be avoided.

Materials and Evidence

The submission dossier must include labels and instructions for use in the target country language, and the samples must be identical to the final marketed product. Some countries require a translation accuracy declaration issued by a qualified translation organization or individual.

Symbol explanations must be prepared. If ISO 15223-1 symbols or country-specific symbols are used on labels, their meanings must be explained in the instructions. In regions where symbols are not accepted, text may be required instead.

UDI information must be prepared. Most countries and regions already require UDI for implantable products. The UDI carrier, its location, and the correspondence between UDI-DI and registration certificate information must be planned in advance. The instructions must include the UDI carrier or explain how to access it.

Technical evidence consistent with label content must be prepared. For example, any claims about indications, contraindications, storage conditions, sterilization methods, or expected service life must be supported by test reports or risk management records. If the clinical evaluation report restricts certain populations, the labeling must not exceed that scope.

Version control documentation must be prepared. All label and instruction version numbers, revision dates, reasons for revision, and approval records should be included in the quality system to form an evidence chain. If updates are needed post-market, the regulator and agent must be notified in a timely manner.

Common Errors

Common errors can directly lead to deficiency letters, rejection, or post-market compliance risks. These include:

• Direct use of machine translations without professional medical translation and local regulatory review.
• Copying NMPA Chinese labels without paying attention to target country requirements for warnings, precautions, and contraindications.
• Ignoring target country languages, e.g., some countries require regional languages in addition to the official language.
• Omitting registration certificate numbers, local agent information, or manufacturer information.
• Misusing CE/FDA symbols without converting to symbols recognized by the target country.
• Failing to convert units according to local regulations, such as mm versus French.
• No multi-country version control, leading to mixing of versions.
• Placing electronic instruction links on labels when the target country requires printed instructions to accompany the product.
• Neglecting the approval process for post-market label changes and making unauthorized modifications.

Company Preparation Checklist

Companies can use the following checklist to prepare item by item and avoid omissions:

• Complete the target country regulatory scope and classification determination, and update the registration strategy.
• Establish a labeling localization SOP covering translation, review, approval, and change processes.
• Collect and review original country labels, instructions, and supporting technical documents.
• Contract a local agent or authorized representative and confirm their information will appear on the label.
• Use professional medical device translation services and retain proof of translator qualifications.
• Design label layout, symbols, and units according to target country requirements.
• Plan and implement UDI for implantable products.
• Before submitting the registration, conduct a mock review to check label content against technical files and clinical evaluation.
• After market launch, review labels and instructions at least annually and update change records.

AIMEILI's Perspective

The most common misjudgment is thinking that once translation is complete, localization is done. In fact, localization is a regulatory task, not just a language task. Every statement on a label can be treated by regulators as a claim that requires evidence.

Early in the project, companies should conduct a regulatory survey of the target country and jointly develop a requirement list with the local agent. Do not wait until just before registration submission to address labeling; otherwise, the review timeline will be compressed, and the probability of deficiency letters will increase.

Reusable materials include product test reports, risk management documents, clinical evidence, and quality system records. Items that must be localized include language, local agent information, regulatory requirements, warning symbols, measurement units, and certain indication wordings.

Local agents, certificate control rights, and change and renewal management are very important. Registration certificates are usually held by the applicant, but many countries require the local agent to communicate with the regulatory authority. If the address or agent changes during the certificate validity period, timely filing is required. If the agent is uncooperative, certificate renewal and labeling changes may be hindered.

For multi-country registration, it is recommended to manage with a “core content + country-specific differences” approach, establishing a terminology table and template library. When entering each new country, only incremental modifications are made, reducing the risk of repeated compilation and deficiency responses. AIMEILI advises companies to treat labeling localization as a subproject within the registration project, assign dedicated personnel, and include it in the critical path.

Frequently Asked Questions

Can old label versions still be used?

Old label versions may be used during a transition period, but they must comply with the target country's regulations and the approved registration certificate. If the certificate has already approved a new version, the old version generally cannot be manufactured or sold. Companies should confirm the transition period with the regulator or agent and develop a switch plan.

Does localization have to be done by the local agent?

It is not mandatory for the agent to perform the translation personally. Companies can do it themselves or commission a translation agency, but the final version submitted to the regulator must comply with local regulations. The local agent is usually responsible for reviewing and confirming compliance, especially addresses, registration information, and contact channels. If the agent does not approve, the risk is high.

Can one version of labels and instructions be used for multiple countries?

Unless the target countries have identical requirements and the regulations allow it, using the same version is not recommended. GHWP member states differ in language, regulations, and review focus. Country-specific versions should be generated from a common core template, and each version should have its own version number and control record.

Source: Compiled from the AIMEILI registration practice database, medical device international registration knowledge base, and public regulatory information. Specific projects should conform to the latest requirements and product documentation of the target country's regulatory authority.